The impact of pregnancy and associated hormones on the pharmacokinetics of Δ⁹-tetrahydrocannabinol

References

• Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223–228. doi: 10.31887/DCNS.2020.22.3/mcrocq
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Edery H. Chapter 2: structure-activity relationships in the Cannabinoid series. In: Mechoulam R, editor. Marijuana: chemistrry, pharmacology, metabolism, and clinical effects. (NY): Academic Press Inc; 1973. p. 101–136.
   Google Scholar
• Mechoulam R, Gaoni Y. A total synthesis of dl-Δ 1 -tetrahydrocannabinol, the active constituent of hashish 1. J Am Chem Soc. 1965;87(14):3273–3275. Available from: https://pubs.acs.org/sharingguidelines
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. MARINOL (dronabinol) capsules, for oral use, CIII [Internet]. North Chicago (IL); 2017. Available from: www.fda.gov/medwatch
   Google Scholar
• Azofeifa A, Mattson ME, Schauer G, et al. National Estimates of Marijuana Use and Related Indicators — National Survey on Drug Use and Health, United States, 2002–2014. 2016.
   Google Scholar
• Center for Behavioral Health Statistics S. Results from the 2015 National survey on drug use and health: detailed tables.
   Google Scholar
• Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). 2015. https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf
   Google Scholar
• Report: state medical cannabis laws [internet]. National Conference of State Legislatures. 2023 [cited 2023 Jun 30]. Available from: https://www.ncsl.org/health/state-medical-cannabis-laws#:~:text=As%20of%20Feb.,medical%20use%20of%20cannabis%20products
   Google Scholar
• ElSohly MA, Mehmedic Z, Foster S, et al. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of Current data in the United States. Biol Psychiatry. 2016;79(7):613–619. doi: 10.1016/j.biopsych.2016.01.004
   PubMed Web of Science ®Google Scholar
• Steigerwald S, Wong PO, Khorasani A, et al. The form and content of cannabis products in the United States. J Gen Intern Med. 2018;33(9):1426–1428. doi: 10.1007/s11606-018-4480-0
   PubMed Web of Science ®Google Scholar
• Medical Association A Cannabinoid dose and label accuracy in edible medical cannabis products [internet]. 2015. Available from: https://jamanetwork.com/
   Google Scholar
• Schlienz NJ, Spindle TR, Cone EJ, et al. Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug Alcohol Depend. 2020;211:211. doi: 10.1016/j.drugalcdep.2020.107969
   Web of Science ®Google Scholar
• Volkow ND, Han B, Compton, WM, et al. Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States. JAMA. 2019;322(2):167–169. doi: 10.1001/jama.2019.7982”101
   PubMed Web of Science ®Google Scholar
• Passey ME, Sanson-Fisher RW, D’Este CA, et al. Alcohol and cannabis use during pregnancy: clustering of risks. Drug Alc Dep. 2014 Jan 1;134:44–50. doi: 10.1016/j.drugalcdep.2013.09.008
   PubMed Web of Science ®Google Scholar
• Cannabis (marijuana) research report can marijuana use during and after pregnancy harm the baby? [internet]. National Institute on drug abuse. 2023 [cited 2023 Jun 30]. Available from: https://nida.nih.gov/publications/research-reports/marijuana/can-marijuana-use-during-pregnancy-harm-baby
   Google Scholar
• Chang JC, Tarr JA, Holland CL, et al. Beliefs and attitudes regarding prenatal marijuana use: perspectives of pregnant women who report use. Drug Alcohol Depend. 2019;196:14–20. doi: 10.1016/j.drugalcdep.2018.11.028
   PubMed Web of Science ®Google Scholar
• Mark K, Gryczynski J, Axenfeld E, et al. Pregnant women’s Current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. J Addict Med. 2017;11(3):211–216. doi: 10.1097/ADM.0000000000000299
   PubMed Web of Science ®Google Scholar
• Young-Wolff KC, Sarovar V, Tucker L-Y, et al. Association of Nausea and vomiting in pregnancy with prenatal marijuana use. JAMA Intern Med. 2018;178(10):1423–1424. doi: 10.1001/jamainternmed.2018.3581
   PubMed Web of Science ®Google Scholar
• Bayrampour H, Zahradnik M, Lisonkova S, et al. Women’s perspectives about cannabis use during pregnancy and the postpartum period: an integrative review. Prev Med [Internet]. 2019;119:17–23. doi: 10.1016/j.ypmed.2018.12.002
   PubMed Web of Science ®Google Scholar
• Ko JY, Farr SL, Tong VT, et al. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol. 2015;213(2):.e201.1–.e201.10. doi: 10.1016/j.ajog.2015.03.021
   Web of Science ®Google Scholar
• Holland CL, Nkumsah MA, Morrison P, et al. “Anything above marijuana takes priority”: obstetric providers’ attitudes and counseling strategies regarding perinatal marijuana use. Patient Educ Couns. 2016;99(9):1446–1451. doi: 10.1016/j.pec.2016.06.003
   PubMed Web of Science ®Google Scholar
• Cook JL, Blake JM. Cannabis: implications for pregnancy, fetal development, and longer-term health outcomes. J Obstet Gynaecol Canada [Internet]. 2018;40(9):1204–1207. doi: https://doi.org/10.1016/j.jogc.2018.06.004
   PubMedGoogle Scholar
• Lemberger L, Martz R, Rodda B. Comparative pharmacology of Δ9-tetrahydrocannabinol and its metabolite, 11-OH-Δ9-tetrahydrocannabinol. J Clin Investig. 1973;52(10):2411–2417. doi: 10.1172/JCI107431
   PubMed Web of Science ®Google Scholar
• Zagzoog A, Cabecinha A, Abramovici H, et al. Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from cannabis sativa and non-cannabis phytomolecules. Front Pharmacol. 2022;13. doi: 10.3389/fphar.2022.956030
   Web of Science ®Google Scholar
• Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215. doi: 10.1038/sj.bjp.0707442
   PubMed Web of Science ®Google Scholar
• Grant KS, Petroff R, Isoherranen N, et al. Cannabis use during pregnancy: pharmacokinetics and effects on child development. Pharmacol Ther. 2018;182:133–151. doi: 10.1016/j.pharmthera.2017.08.014
   PubMed Web of Science ®Google Scholar
• Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58(9):1017–1030. doi: 10.1002/glia.20983
   PubMed Web of Science ®Google Scholar
• Blanton HL, Barnes RC, McHann MC, et al. Sex differences and the endocannabinoid system in pain. Pharmacol Biochem Behav. 2021;202:202. doi: 10.1016/j.pbb.2021.173107
   Web of Science ®Google Scholar
• McKinney MK, Cravatt BE. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74(1):411–432. doi: 10.1146/annurev.biochem.74.082803.133450
   PubMedGoogle Scholar
• Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A [Internet]. 2001;98(16):9371–9376. doi: 10.1073/pnas.161191698
   PubMed Web of Science ®Google Scholar
• Dinh TP, Carpenter D, Leslie FM, Freund TF, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA. 2002;99(16):10819–24. doi: 10.1073/pnas/152334899
   PubMed Web of Science ®Google Scholar
• Maccarrone M, De Felici M, Bari M, et al. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. Eur J Biochem. 2000;267(10):2991–2997. doi: 10.1046/j.1432-1327.2000.01316.x
   PubMedGoogle Scholar
• Rodriguez De Fonseca F, Cebeira M, Ramos JA, et al. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci. 1993;54(3):159–170. doi: 10.1016/0024-3205(94)00585-0
   Web of Science ®Google Scholar
• González S, Bisogno T, Wenger T, et al. Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun. 2000;270(1):260–266. doi: 10.1006/bbrc.2000.2406
   PubMed Web of Science ®Google Scholar
• Craft RM, Kandasamy R, Davis SM. Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ9-tetrahydrocannabinol in the rat. Pain. 2013;154(9):1709–1717. doi: 10.1016/j.pain.2013.05.017
   PubMed Web of Science ®Google Scholar
• Tseng AH, Craft RM. Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol [Internet]. 2001;430(1):41–47. doi: 10.1016/S0014-2999(01)01267-5
   PubMed Web of Science ®Google Scholar
• Smoker MP, Mackie K, Lapish CC, et al. Self-administration of edible Δ9-tetrahydrocannabinol and associated behavioral effects in mice. Drug Alcohol Depend. 2019;199:106–115. doi: 10.1016/j.drugalcdep.2019.02.020
   PubMed Web of Science ®Google Scholar
• Parks C, Jones BC, Moore BM, et al. Sex and strain variation in initial sensitivity and rapid tolerance to Δ9–tetrahydrocannabinol. Cannabis Cannabinoid Res. 2020;5(3):231–245. doi: 10.1089/can.2019.0047
   PubMedGoogle Scholar
• Boehnke KF, Gangopadhyay S, Clauw DJ, et al. Qualifying conditions of medical cannabis license holders in the United States. Health Aff. 2019;38(2):295–302. doi: 10.1377/hlthaff.2018.05266
   PubMed Web of Science ®Google Scholar
• Matheson J, Sproule B, Di Ciano P, et al. Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. Psychopharmacol (Berl). 2020;237(2):305–316. doi: 10.1007/s00213-019-05369-y
   PubMed Web of Science ®Google Scholar
• Pabon E, de Wit H. Effects of oral delta-9-tetrahydrocannabinol in women during the follicular phase of the menstrual cycle. Cannabis Cannabinoid Res. 2023;8(6):1117–1125. doi: 10.1089/can.2022.0045
   PubMedGoogle Scholar
• Sun X, Dey SK. Endocannabinoid signaling in female reproduction. ACS Chem Neurosci. 2012;3(5):349–355. doi: 10.1021/cn300014e
   PubMed Web of Science ®Google Scholar
• Correa F, Wolfson ML, Valchi P, et al. Endocannabinoid system and pregnancy. Reproduction. 2016;152(6):R191–R200. doi: 10.1530/REP-16-0167
   PubMed Web of Science ®Google Scholar
• Ezechukwu HC, Diya CA, Shrestha N, et al. Role for endocannabinoids in early pregnancy: recent advances and the effects of cannabis use. Am J Physiol Endocrinol Metab [Internet]. 2020;319(3):E557–E561. doi: 10.1152/ajpendo.00210.2020
   PubMed Web of Science ®Google Scholar
• Kozakiewicz ML, Grotegut CA, Howlett AC, Endocannabinoid system in pregnancy maintenance and labor: a mini-review. Front Endocrinol. 2021;12: Frontiers Media S.A. 10.3389/fendo.2021.699951
   PubMed Web of Science ®Google Scholar
• Schneider M. Cannabis use in pregnancy and early life and its consequences: animal models. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):383–393. doi: 10.1007/s00406-009-0026-0
   PubMed Web of Science ®Google Scholar
• Fride E, Gobshtis N, Dahan H, et al. Chapter 6 the endocannabinoid system during development: emphasis on perinatal events and delayed effects. Vitam Horm. 2009;81:139–158.
   PubMed Web of Science ®Google Scholar
• Habayeb OMH, Taylor AH, Evans MD, et al. Plasma levels of the endocannabinoid anandamide in women—A potential role in pregnancy maintenance and labor? J Clin Endocrinol Metab. 2004;89(11):5482–5487. doi: 10.1210/jc.2004-0681
   PubMed Web of Science ®Google Scholar
• Fonseca BM, Correia-da-Silva G, Taylor AH, et al. The endocannabinoid 2-arachidonoylglycerol (2-AG) and metabolizing enzymes during rat fetoplacental development: a role in uterine remodelling. Int J Biochem Cell Biol. 2010;42(11):1884–1892. doi: 10.1016/j.biocel.2010.08.006
   PubMed Web of Science ®Google Scholar
• Maia J, Fonseca BM, Teixeira N, et al. The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders. Hum Reprod Update. 2020;26(4):586–602. doi: 10.1093/humupd/dmaa005
   PubMed Web of Science ®Google Scholar
• Bazyar H, Nasiri K, Ghanbari P, et al. Circulating endocannabinoid levels in pregnant women with gestational diabetes mellitus: a case–control study. BMC Endocr Disord. 2022;22(1):22. doi: 10.1186/s12902-022-01182-5
   PubMed Web of Science ®Google Scholar
• Olyaei AMYF, Campbell LR, Roberts VHJ, et al. Animal models evaluating the impact of prenatal exposure to tobacco and marijuana. Clin Obstet Gynecol. 2022;65(2):334–346. doi: 10.1097/GRF.0000000000000693
   PubMed Web of Science ®Google Scholar
• Marijuana Use During Pregnancy And Lactation. The American College of Obstetricians and Gynecologists; 2017. p. 205–209. Available from: www.acog.org/About-ACOG/ACOG-Departments/
   Google Scholar
• Wu C-S, Jew CP, Lu H-C. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol. 2011;6(4):459–480. doi: 10.2217/fnl.11.27
   PubMedGoogle Scholar
• Grewen K, Salzwedel AP, Gao W. Functional connectivity disruption in neonates with prenatal marijuana exposure. Front Hum Neurosci. 2015;9. doi: 10.3389/fnhum.2015.00601
   PubMed Web of Science ®Google Scholar
• Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol. 1998;20(3):293–306. doi: 10.1016/S0892-0362(97)00091-3
   PubMed Web of Science ®Google Scholar
• Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22(3):325–336. doi: 10.1016/S0892-0362(00)00066-0
   PubMed Web of Science ®Google Scholar
• El MH, Hudziak JJ, Tiemeier H, et al. Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls. Drug Alcohol Depend. 2011;118(2–3):470–474. doi: 10.1016/j.drugalcdep.2011.03.004
   PubMed Web of Science ®Google Scholar
• Leech SL, Richardson GA, Goldschmidt L, et al. Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds. Neurotoxicol Teratol. 1999;21(2):109–118. doi: 10.1016/S0892-0362(98)00042-7
   PubMed Web of Science ®Google Scholar
• Huang W, Czuba LC, Manuzak JA, et al. Objective identification of cannabis use levels in clinical populations is critical for detecting pharmacological outcomes. Cannabis Cannabinoid Res. 2021;1–13. doi: 10.1089/can.2020.0027
   PubMedGoogle Scholar
• Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of timeline follow-back for self-reported use of cannabis and other illicit substances — systematic review and meta-analysis. Add Behav. 2012;37(3):225–233. doi: 10.1016/j.addbeh.2011.11.025
   PubMed Web of Science ®Google Scholar
• Clark CB, Zyambo CM, Li Y, et al. The impact of non-concordant self-report of substance use in clinical trials research. Add Behav. 2016;58:74–79. doi: 10.1016/j.addbeh.2016.02.023
   PubMed Web of Science ®Google Scholar
• Khalili P, Nadimi AE, Baradaran HR, et al. Validity of self-reported substance use: research setting versus primary health care setting. Subst Abuse Treat Prev Policy. 2021;16(1). doi: 10.1186/s13011-021-00398-3
   PubMed Web of Science ®Google Scholar
• Harrison L The validity of self-reported drug use in survey research: an overview and critique of research methods.
   Google Scholar
• Ko JY, Tong VT, Bombard JM, et al. Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: a population-based study. Drug Alcohol Depend. 2018;187:72–78. doi: 10.1016/j.drugalcdep.2018.02.017
   PubMed Web of Science ®Google Scholar
• Warshak CR, Regan J, Moore B, et al. Association between marijuana use and adverse obstetrical and neonatal outcomes. J Perinatol. 2015;35(12):991–995. doi: 10.1038/jp.2015.120
   PubMed Web of Science ®Google Scholar
• Verrico CD, Liu S, Bitler EJ, et al. Delay- and dose-dependent effects of Δ9-tetrahydrocannabinol administration on spatial and object working memory tasks in adolescent rhesus monkeys. Neuropsychopharmacology. 2012;37(6):1357–1366. doi: 10.1038/npp.2011.321
   PubMed Web of Science ®Google Scholar
• Manuzak JA, Gott TM, Kirkwood JS, et al. Heavy cannabis use associated with reduction in activated and inflammatory immune cell frequencies in antiretroviral therapy–treated human immunodeficiency virus–infected individuals. Clinl Infect Dis. 2018;66(12):1872–1882. doi: 10.1093/cid/cix1116
   PubMed Web of Science ®Google Scholar
• Newmeyer MN, Swortwood MJ, Barnes AJ, et al. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem. 2016;62(12):1579–1592. doi: 10.1373/clinchem.2016.263475
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–360. doi: 10.2165/00003088-200342040-00003
   PubMed Web of Science ®Google Scholar
• Watanabe K, Yamaori S, Funahashi T, et al. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007;80(15):1415–1419. doi: 10.1016/j.lfs.2006.12.032
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Iwawaki Y, Watanabe K, et al. Metabolism of Δ9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci. 1995;56(23–24):2089–2095. doi: 10.1016/0024-3205(95)00193-A
   PubMed Web of Science ®Google Scholar
• Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of Δ9- tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther. 2009;85(3):273–276. doi: 10.1038/clpt.2008.213
   PubMed Web of Science ®Google Scholar
• Patilea-Vrana GI, Unadkat JD. Quantifying hepatic enzyme kinetics of (-)-∆9-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling. Drug Metab Dispos. 2019;47(7):743–752. doi: 10.1124/dmd.119.086470
   PubMed Web of Science ®Google Scholar
• Naef M, Russmann S, Petersen-Felix S, et al. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci. 2004;93(5):1176–1184. doi: 10.1002/jps.20037
   PubMed Web of Science ®Google Scholar
• Metz TD, McMillin GA, Silver RM, et al. Quantification of prenatal marijuana use: evaluation of the correlation between self-report, serum, urine and umbilical cord assays among women delivering at two urban Colorado hospitals. Addiction. 2022;117(1):172–181. doi: 10.1111/add.15606
   PubMed Web of Science ®Google Scholar
• Narimatsu S, Watanabe K, Matsunaga T, et al. Cytochrome P-450 isozymes in metabolic activation of delta 9-tetrahydrocannabinol by rat liver microsomes. Drug Metab Dispos. 1990;18(6):943–948.
   PubMed Web of Science ®Google Scholar
• Beers JL, Authement AK, Isoherranen N, et al. Cytosolic enzymes generate cannabinoid metabolites 7-carboxycannabidiol and 11-nor-9-carboxytetrahydrocannabinol. ACS Med Chem Lett. 2023;14(5):614–620. doi: 10.1021/acsmedchemlett.3c00017
   PubMed Web of Science ®Google Scholar
• Mazur A, Lichti CF, Prather PL, et al. Characterization of human hepatic and extrahepatic UDP- glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009;37(7):1496–1504. doi: 10.1124/dmd.109.026898
   PubMed Web of Science ®Google Scholar
• Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34(3):352–363. doi: 10.1038/clpt.1983.179
   PubMed Web of Science ®Google Scholar
• Fabritius M, Staub C, Mangin P, et al. Distribution of free and conjugated cannabinoids in human bile samples. Forensic Sci Int. 2012;223(1–3):114–118. doi: 10.1016/j.forsciint.2012.08.013
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 16078, dronabinol [internet]. PubChem. [cited 2023 Sep 27]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dronabinol
   Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 644022, 11-hydroxytetrahydrocannabinol [internet]. PubChem. [cited 2023 Sep 27]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11-Hydroxytetrahydrocannabinol
   Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 108207, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol [internet]. PubChem. [cited 2023 Sep 27]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11-Nor-9-carboxy-delta-9-tetrahydrocannabinol
   Google Scholar
• Thomas BF, Compton DR, Martin BA. Characterization of the lipophilicity of natural and synthetic analogs of L\9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Toxicol. 1990;255:624–630.
   Google Scholar
• O’Neil MJ. The Merck Index - an encyclopedia of chemicals, drugs, and biologicals. 15th ed. Cambridge (UK): Royal Society of Chemistry; 2013.
   Google Scholar
• ChemAxon. Chemicalize was used for prediction of pKa of 11-OH-THC and 11-COOH-THC [internet]. 2023 [cited 2023 Oct 21]. Available from: https://chemicalize.com/
   Google Scholar
• Lemberger L, Crabtree RE, Rowe HM. 11-Hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Sci (1979). 1972;177(4043):62–64. doi: 10.1126/science.177.4043.62
   Web of Science ®Google Scholar
• Glaz-Sandberg A, Dietz L, Nguyen H, et al. Pharmacokinetics of 11-nor-9-carboxy-Δ9- tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin Pharmacol Ther. 2007;82(1):63–69. doi: 10.1038/sj.clpt.6100199
   PubMed Web of Science ®Google Scholar
• Giroud C, Menetrey A, Augsburger M, et al. Δ9-THC, 11-OH-Δ9-THC and Δ9-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int. 2001;123(2–3):159–164. doi: 10.1016/S0379-0738(01)00538-2
   PubMed Web of Science ®Google Scholar
• Skopp G, Ètsch LP, Mauden M, et al. Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-Δ9-carboxy tetrahydrocannabinol glucuronide. Forensic Sci Int. 2002;126(1):17–23. doi: 10.1016/S0379-0738(02)00023-3
   PubMed Web of Science ®Google Scholar
• Lindgren J-E, Ohlsson A, Agurell S, et al. Clinical effects and plasma levels of a 9-tetrahydrocannabinol (A 9-THC) in heavy and light users of cannabis. Psychopharmacology. 1981;74(3):208–212. doi: 10.1007/BF00427095
   PubMed Web of Science ®Google Scholar
• Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39(10):1607–1616. doi: 10.1017/S0033291709005522
   PubMed Web of Science ®Google Scholar
• Barkus E, Morrison PD, Vuletic D, et al. Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol. 2011;25(11):1462–1468. doi: 10.1177/0269881110382465
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren J‐E, Wahlen A, et al. Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28(3):409–416. doi: 10.1038/clpt.1980.181
   PubMed Web of Science ®Google Scholar
• Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992;16(4):228–35. doi: 10.1093/jat/16.4.228
   PubMed Web of Science ®Google Scholar
• Hunt AC, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther. 1980;215(1):35–44.
   PubMed Web of Science ®Google Scholar
• Lemberger L, Weiss JL, Watanabe AM, et al. Delta-9-tetrahydrocannabinol temporal correlation of the psychological effects and blood levels after various routes of administration. N Engl J Med. 1972;286(13):685–688. doi: 10.1056/NEJM197203302861303
   PubMed Web of Science ®Google Scholar
• Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.
   Google Scholar
• Ohlsson A, Lindgren J-E, Wahlen A, et al. Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis users. Biol Mass Spectrom. 1982;9(1):6–10. doi: 10.1002/bms.1200090103
   Google Scholar
• Wall ME, Perez-Reyes M. The metabolism of Δ 9 -tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol. 1981;21(S1):178S–189S. doi: 10.1002/j.1552-4604.1981.tb02594.x
   PubMedGoogle Scholar
• Lemberger L, Silberstein SD, Axelrod J, et al. Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science. 1970;170(3964):1320–1322. doi: 10.1126/science.170.3964.1320
   PubMed Web of Science ®Google Scholar
• Lemberger L, Tamarkin NR, Axelrod J, et al. Delta-9-Tetrahydrocannabinol: Metabolism and Disposition in Long-Term Marihuana Smokers. Science. 1971;173(3991):72–74. doi: 10.1126/science.173.3991.72
   PubMed Web of Science ®Google Scholar
• Garrett ER, Hunt CA. Pharmacokinetics of Δ9-tetrahydrocannabinol in dogs. J Pharm Sci. 1977;66(3):395–407. doi: 10.1002/jps.2600660322
   PubMed Web of Science ®Google Scholar
• Patilea-Vrana GI, Unadkat JD. Development and verification of a linked Δ 9 -THC/11-OH-THC physiologically based pharmacokinetic model in healthy, nonpregnant population and extrapolation to pregnant women. Drug Metab Dispos. 2021;49(7):509. doi: 10.1124/dmd.120.000322
   PubMed Web of Science ®Google Scholar
• Klausner H, Wilcox H, Dingell J. The use of zonal ultracentrifugation in the investigation of the binding of delta9-tetrahydrocannabinol by plasma lipoproteins. Drug Metab Dispos. 1975;3(4):314–319.
   PubMed Web of Science ®Google Scholar
• Yabut KCB, Isoherranen N. Impact of intracellular lipid binding proteins on endogenous and xenobiotic ligand metabolism and disposition. Drug Metab Dispos. 2023;51(6):700–717. doi: 10.1124/dmd.122.001010
   PubMedGoogle Scholar
• Elmes MW, Kaczocha M, Berger WT, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015;290(14):8711–8721. doi: 10.1074/jbc.M114.618447
   PubMed Web of Science ®Google Scholar
• Spiro AS, Wong A, Boucher AA, et al. Enhanced brain disposition and effects of Δ 9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice. PLoS One. 2012;7(4):e35937. doi: 10.1371/journal.pone.0035937
   PubMed Web of Science ®Google Scholar
• Bonhomme-Faivre L, Benyamina A, Reynaud M, et al. PRECLINICAL STUDY: disposition of Δ 9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict Biol. 2008;13(3–4):295–300. doi: 10.1111/j.1369-1600.2008.00096.x
   PubMed Web of Science ®Google Scholar
• Chen X, Unadkat JD, Mao Q. Maternal and fetal exposure to (-)-Δ9-tetrahydrocannabinol and its major metabolites in pregnant mice is differentially impacted by P-glycoprotein and breast cancer resistance protein. Drug Metab Dispos. 2023;51(3):269–275. doi: 10.1124/dmd.122.001110
   PubMed Web of Science ®Google Scholar
• Chen X, Unadkat JD, Mao Q. Tetrahydrocannabinol and its major metabolites are not (or are poor) substrates or inhibitors of human P-Glycoprotein [ATP-binding cassette (ABC) B1] and breast cancer resistance protein (ABCG2). Drug Metab Dispos. 2021;49(10):910–918. doi: 10.1124/dmd.121.000505
   PubMed Web of Science ®Google Scholar
• Brunet B, Doucet C, Venisse N, et al. Validation of large white pig as an animal model for the study of cannabinoids metabolism: application to the study of THC distribution in tissues. Forensic Sci Int. 2006;161(2–3):169–174. doi: 10.1016/j.forsciint.2006.04.018
   PubMed Web of Science ®Google Scholar
• Kudo K, Nagata T, Kimura K, et al. Sensitive determination of Δ9-tetrahydrocannabinol in human tissues by GC-MS. J Anal Toxicol. 1995;19(2):87–90. doi: 10.1093/jat/19.2.87
   PubMed Web of Science ®Google Scholar
• Saenz SR, Lewis RJ, Angier MK, et al. Postmortem fluid and tissue concentrations of THC, 11-OH-THC and THC-COOH†. J Anal Toxicol. 2017;41(6):508–516. doi: 10.1093/jat/bkx033
   PubMed Web of Science ®Google Scholar
• Kreuz DS, Axelrod J. Delta-9-Tetrahydrocannabinol: Localization in Body Fat. Science (1979). 1973;179(4071):391–393. doi: 10.1126/science.179.4071.391
   Web of Science ®Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804. doi: 10.1002/cbdv.200790152
   PubMed Web of Science ®Google Scholar
• Stott C, White L, Wright S, et al. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013;2(1):1–15. doi: 10.1186/2193-1801-2-236
   PubMedGoogle Scholar
• Huestis MA, Henningfield JE, Conet EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana*. J Anal Toxicol. 1992;16(5):276–282.
   PubMed Web of Science ®Google Scholar
• Lunn S, Diaz P, O’Hearn S, et al. Human pharmacokinetic parameters of orally administered Δ9-tetrahydrocannabinol capsules are altered by fed versus fasted conditions and sex differences. Cannabis Cannabinoid Res [Internet]. [cited 2023 May 9];4. Available from: https://pubmed.ncbi.nlm.nih.gov/31872060/
   Google Scholar
• Huestis MA, Henningfield JE, Conet EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana*. J Anal Toxicol. 1992;16(5):276–282. doi: 10.1093/jat/16.5.276
   PubMed Web of Science ®Google Scholar
• Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec. 1971;8(4):391–402.
   PubMedGoogle Scholar
• Anttila S, Tuominen P, Hirvonen A, et al. CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmaco. 2001;11(6): 501–509. doi: 10.1097/00008571-200108000-00005
   Google Scholar
• Parikh N, Kramer WG, Khurana V, et al. Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clin Pharmacol. 2016;8:155–162. doi: 10.2147/CPAA.S115679
   PubMedGoogle Scholar
• Oh DA, Parikh N, Khurana V, et al. Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clin Pharmacol. 2017;9:9–17. doi: 10.2147/CPAA.S119676
   PubMed Web of Science ®Google Scholar
• Kumar AR, Patilea-Vrana GI, Anoshchenko O, et al. Characterizing and quantifying extrahepatic metabolism of (−)-Δ 9 -tetrahydrocannabinol (THC) and its psychoactive metabolite, (±)-11-hydroxy-Δ 9 -THC (11-OH-THC). Drug Metab Dispos. 2022;50(6):734–740. doi: 10.1124/dmd.122.000868
   PubMed Web of Science ®Google Scholar
• Spindle TR, Cone EJ, Herrmann ES, et al. Pharmacokinetics of cannabis brownies: a controlled examination of Δ9-tetrahydrocannabinol and metabolites in blood and oral fluid of healthy adult males and females. J Anal Toxicol. 2020;44(7):661–671. doi: 10.1093/jat/bkaa067
   PubMed Web of Science ®Google Scholar
• Nadulski T, Pragst F, Weinberg G, et al. Randomized, Double-Blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of D 9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005;27(6):799–810. doi: 10.1097/01.ftd.0000177223.19294.5c
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875–894. doi: 10.1517/17425255.2.6.875
   PubMed Web of Science ®Google Scholar
• Wiley JL, Burston JJ. Sex differences in delta 9-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats. Neurosci Lett. 2014;576:51–55. doi: 10.1016/j.neulet.2014.05.057
   PubMed Web of Science ®Google Scholar
• Craft RM, Haas AE, Wiley JL, et al. Gonadal hormone modulation of ∆9-tetrahydrocannabinol-induced antinociception and metabolism in female versus male rats. Pharmacol Biochem Behav. 2017;152:36–43. doi: 10.1016/j.pbb.2016.09.006
   PubMed Web of Science ®Google Scholar
• Narimatsu S, Watanabe K, Matsunaga T, et al. Cytochrome P-450 isozymes involved in the oxidative metabolism of delta9-tetrahydrocannabinol by liver microsomes of adult female rats. Drug Metab Dispos. 1991;20:79–83.
   Web of Science ®Google Scholar
• Narimatsu S, Watanabe K, Yamamoto I, et al. Sex difference in the oxidative metabolism of Δ9-tetrahydrocannabinol in the rat. Biochem Pharmacol. 1991;41(8):1187–1194. doi: 10.1016/0006-2952(91)90657-Q
   PubMed Web of Science ®Google Scholar
• Watanabe K, Matsunaga T, Narimatsu S, et al. Sex difference in hepatic microsomal aldehyde oxygenase activity in different strains of mice. Res Commun Chem Pathol Pharmacol. 1992;78(3):373–376.
   PubMedGoogle Scholar
• Jeong H. Altered drug metabolism during pregnancy: Hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010;6(6):689–699. doi: 10.1517/17425251003677755
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013;41(2):256–262. doi: 10.1124/dmd.112.050245
   PubMed Web of Science ®Google Scholar
• Balhara A, Kumar AR, Unadkat JD. Predicting human fetal drug exposure through maternal-fetal PBPK modeling and in vitro or ex vivo studies. J Clin Pharmacol. 2022;62(S1):S94–S114. doi: 10.1002/jcph.2117
   PubMedGoogle Scholar
• Abduljalil K, Furness P, Johnson TN, et al. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(6):365–396. doi: 10.2165/11597440-000000000-00000
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pregnancy-induced changes in pharmacokinetics a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989–1008. doi: 10.2165/00003088-200544100-00001
   PubMed Web of Science ®Google Scholar
• Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal–infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006;2(6):947–960. doi: 10.1517/17425255.2.6.947
   PubMed Web of Science ®Google Scholar
• Fuglsang J, Skjærbæk C, Espelund U, et al. Ghrelin and its relationship to growth hormones during normal pregnancy. Clin Endocrinol (Oxf). 2005;62(5):554–559. doi: 10.1111/j.1365-2265.2005.02257.x
   PubMed Web of Science ®Google Scholar
• Dehkhoda F, Lee CMM, Medina J, et al. The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Front Endocrinol. 2018;9. Frontiers Media S.A.
   PubMed Web of Science ®Google Scholar
• Soldin OP, Guo T, Weiderpass E, et al. Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. Fertil Steril. 2005;84(3):701–710. doi: 10.1016/j.fertnstert.2005.02.045
   PubMed Web of Science ®Google Scholar
• Sever R, Glass CK. Signaling by nuclear receptors. Cold Spring Harb Perspect Biol. 2013;5(3):a016709–a016709. doi: 10.1101/cshperspect.a016709
   PubMed Web of Science ®Google Scholar
• Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011;96(5):1533–1540. doi: 10.1210/jc.2010-2395
   PubMed Web of Science ®Google Scholar
• Kerlan V, Nahoult K, Le MartelotS M-T, et al. Longitudinal study of maternal plasma bioavailable testosterone and androstanediol glucuronide levels during pregnancy. Clin Endocrinol (Oxf). 1994;40(2):263–267. doi: 10.1111/j.1365-2265.1994.tb02478.x
   PubMed Web of Science ®Google Scholar
• Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013;41(2):263–269. doi: 10.1124/dmd.112.046276
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Daujat M, Pascussi JM, et al. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem. 2002;277(1):209–217. doi: 10.1074/jbc.M107228200
   PubMed Web of Science ®Google Scholar
• Papageorgiou I, Grepper S, Unadkat JD. Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013;41(2):281–290. doi: 10.1124/dmd.112.049015
   PubMed Web of Science ®Google Scholar
• Liddle C, Goodwin BJ, George J, et al. Separate and interactive regulation of Cytochrome P450 3A4 by Triiodothyronine, dexamethasone, and growth hormone in cultured Hepatocytes*. J Clin Endocrinol Metab. 1998;83(7):2411–2416. Available from: https://academic.oup.com/jcem/article/83/7/2411/2865468
   PubMed Web of Science ®Google Scholar
• Zhang Z, Farooq M, Prasad B, et al. Prediction of gestational age–dependent induction of in vivo Hepatic CYP3A activity based on HepaRG cells and human hepatocytes. Drug Metab Dispos. 2015;43(6):836–842. doi: 10.1124/dmd.114.062984
   PubMed Web of Science ®Google Scholar
• Jeong H, Choi S, Song JW, et al. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008;38(1):62–75. doi: 10.1080/00498250701744633
   PubMed Web of Science ®Google Scholar
• Khatri R, Fallon JK, Sykes C, et al. Pregnancy-related hormones increase UGT1A1-mediated labetalol metabolism in human hepatocytes. Front Pharmacol. 2021;12:12. doi: 10.3389/fphar.2021.655320
   Web of Science ®Google Scholar
• Cho S-J, Ning M, Zhang Y, et al. 17β-Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor α. Acta Pharm Sin B. 2016;6(5):504–509. doi: 10.1016/j.apsb.2016.04.005
   PubMed Web of Science ®Google Scholar
• Robson SC, Hunter S, Boys RJ, et al. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol Hear Circ Physiol [Internet]. 1989;256(4):H1060–H1065. Available from: www.physiology.org/journal/ajpheart
   PubMedGoogle Scholar
• van Oppen ACC, van der Tweel I, Alsbach GPJ, et al. A longitudinal study of maternal hemodynamics during normal pregnancy. Obstet & Gynecol. 1996;88(1):40–46. doi: 10.1016/0029-7844(96)00069-5
   PubMed Web of Science ®Google Scholar
• Easterling TR, Benedetti TJ, Schmucker BC, et al. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet & Gynecol. 1990;76(6):1061–1069.
   PubMed Web of Science ®Google Scholar
• Nakai A, Sekiya I, Oya A, et al. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with doppler ultrasonography. Arch Gynecol Obstet. 2002;266(1):25–29. doi: 10.1007/PL00007495
   PubMedGoogle Scholar
• Dempsey D, Iii PJ, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther [Internet]. 2002;301(2):594–598. Available from: http://jpet.aspetjournals.org
   PubMed Web of Science ®Google Scholar
• Gerdin E, Salmonson T, Lindberg B, et al. Maternal kinetics of morphine during labour. J Perinat Med. 1990;18(6):479–487. doi: 10.1515/jpme.1990.18.6.479
   PubMed Web of Science ®Google Scholar
• Dean M, Stock B, Patterson RJ, Levy G. Serum protein binding of drugs during and after pregnancy in humans. Clin Pharmacol Ther. 1980;20(2):253–261. doi: 10.1038/clpt.1980.158
   Google Scholar
• Wild R, Feingold KR Effect of pregnancy on lipid metabolism and lipoprotein levels [internet]. Endotext. 2023 [cited 2023 Oct 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK498654/#:~:text=After%20delivery%2C%20lipid%20and%20lipoprotein,insulin%20resistance%20in%20the%20mother
   Google Scholar
• Desoye G, Schweditsch M, Pfeiffer KP, et al. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab [Internet]. 1987;64(4):704–712. Available from: https://academic.oup.com/jcem/article/64/4/704/2653747
   PubMed Web of Science ®Google Scholar
• Rasmussen KM, Yaktine AL. In: Rasmussed, Yaktine, editors. Weight gain during pregnancy: reexamining the guideline. Washington DC: National Academies Press (US); 2009. doi: 10.17226/12584
   Google Scholar
• Thomson AM, Billewicz WZ. Clinical significance of weight trends during pregnancy. Br Med J. 1957;1(5013):243–247. doi: 10.1136/bmj.1.5013.243
   PubMedGoogle Scholar
• Kopp-Hoolihan LE, van Loan MD, Wong WW, et al. Longitudinal assessment of energy balance in well-nourished, pregnant women. Am J Clin Nutr. 1999;69(4):697–704. doi: 10.1093/ajcn/69.4.697
   PubMed Web of Science ®Google Scholar
• Kern F, Everson GT, DeMark B, et al. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J Clin Investig. 1981;68(5):1229–1242. doi: 10.1172/JCI110369
   PubMed Web of Science ®Google Scholar
• Hahm JS, Park JY, Song SC, et al. Gallbladder motility change in late pregnancy and after delivery. Korean J Intern Med. 1997;12(1):16–20. doi: 10.3904/kjim.1997.12.1.16
   PubMedGoogle Scholar
• Davison JM, Dunlop W, Ezimokhai M. 24-hour creatinine clearance during the third trimester of normal pregnancy. Br J Obstet Gynaecol. 1980;87(2):106–109. doi: 10.1111/j.1471-0528.1980.tb04501.x
   PubMedGoogle Scholar
• Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol. 1981;88(1):1–9. doi: 10.1111/j.1471-0528.1981.tb00929.x
   PubMedGoogle Scholar
• Dickinson RG, Hooper WD, Wood B, et al. The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. Br J Clin Pharmacol. 1989;28(1):17–27. doi: 10.1111/j.1365-2125.1989.tb03501.x
   PubMed Web of Science ®Google Scholar
• Lander CM, Smith MT, Chalk JB, et al. Bioavailability and pharmacokinetics of phenytoin during pregnancy. Eur J Clin Pharmacol. 1984;27(1):105–110. doi: 10.1007/BF02395215
   PubMed Web of Science ®Google Scholar
• Tomson T, Lindbom U, Ekqvist B, et al. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia. 1994;35(1):131–135. doi: 10.1111/j.1528-1157.1994.tb02922.x
   PubMed Web of Science ®Google Scholar
• Tomson T, Lindbom U, Ekqvist B, et al. Epilepsy and pregnancy: a pro- spective study of seizure control in relation to free and total plasma concentrations of carba- mazepine and phenytoin. Epilepsia. 1994;35(1):122–130. doi: 10.1111/j.1528-1157.1994.tb02921.x
   PubMed Web of Science ®Google Scholar
• Ke AB, Nallani SC, Zhao P, et al. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol. 2014;77(3):554–570. doi: 10.1111/bcp.12207
   PubMed Web of Science ®Google Scholar
• Hebert MF, Ma X, Naraharisetti SB, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009;85(6):607–614. doi: 10.1038/clpt.2009.5
   PubMed Web of Science ®Google Scholar
• Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84(2):248–253. doi: 10.1038/clpt.2008.1
   PubMed Web of Science ®Google Scholar
• Ke AB, Nallani SC, Zhao P, et al. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. CPT Pharmacometrics Syst Pharmacol. 2012;1(9):1. doi: 10.1038/psp.2012.2
   Google Scholar
• Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–639. doi: 10.1016/j.ajog.2004.08.030
   PubMed Web of Science ®Google Scholar
• Fischer JH, Sarto GE, Hardman J, et al. Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet. 2014;53(4):373–383. doi: 10.1007/s40262-013-0123-0
   PubMed Web of Science ®Google Scholar
• Watts DH, Brown ZA, Tartaglione T, Burchett SK, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991;163(2):226–232. doi: 10.1093/infdis/163.2.226
   PubMed Web of Science ®Google Scholar
• Öhman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure. 2008;17(2):199–202. doi: 10.1016/j.seizure.2007.11.017
   PubMed Web of Science ®Google Scholar
• Franco V, Mazzucchelli I, Gatti G, et al. Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. Ther Drug Monit. 2008;30(4):544–547. doi: 10.1097/FTD.0b013e318178e2a9
   PubMed Web of Science ®Google Scholar
• Fotopoulou C, Kretz R, Bauer S, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009;85(1):60–64. doi: 10.1016/j.eplepsyres.2009.02.011
   PubMed Web of Science ®Google Scholar
• Tran TA, Leppik IE, Sathanandan ST, et al. Lamotrigine Clearance During Pregnancy. Neurology. 2002;59(2):251–255. doi: 10.1212/WNL.59.2.251
   PubMed Web of Science ®Google Scholar
• De Haan G-J, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology [Internet]. 2004;63(3):571–573. doi: 10.1212/01.WNL.0000133213.10244.FD
   PubMed Web of Science ®Google Scholar
• Pennell P, Newport D, Stowe Z, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology [Internet]. 2004;62(2):292–295. doi: 10.1212/01.WNL.0000103286.47129.F8
   PubMed Web of Science ®Google Scholar
• Jana S, Paliwal J. Molecular mechanisms of cytochrome P450 induction: potential for drug-drug interactions. Curr Protein Pept Sci. 2007;8(6):619–628. doi: 10.2174/138920307783018668
   PubMed Web of Science ®Google Scholar
• Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol. 2007;21(4):176–181. doi: 10.1002/jbt.20180
   PubMed Web of Science ®Google Scholar
• Huang L, Bi H, Liu Y, Wang Y, et al. CAR-mediated up-regulation of CYP3A4 expression in LS174T cells by Chinese herbal compounds. Drug Metab Pharmacokinet. 2011;26(4):331–40. doi: 10.2133/dmpk.dmpk-10-rg-115
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang J, Xie W. Xenobiotic nuclear receptor-mediated regulation of UDP-Glucuronosyl-transferases. Curr Drug Metab. 2005;6(4):289–298. doi: 10.2174/1389200054633853
   PubMed Web of Science ®Google Scholar
• Xu C, Yong-Tao Li C, Tony Kong A-N. Induction of phase I, II and III drug metabolism/transport by Xenobiotics. Arch Pharm Res [Internet]. 2005;28(3):249–268. Available from: http://apr.psk.or.kr
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Cavaco I, Yurdakok B, et al. The ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression. J Pharmacol Exp Ther. 2011;338(1):302–309. doi: 10.1124/jpet.110.175075
   PubMed Web of Science ®Google Scholar
• McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000;68(4):356–366. doi: 10.1067/mcp.2000.110215
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Gerbal-Chaloin S, et al. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem. 2001;268(24):6346–6358. doi: 10.1046/j.0014-2956.2001.02540.x
   PubMedGoogle Scholar
• Gerbal-Chaloin S, Pascussi J-M, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001;29(3):242–251.
   PubMed Web of Science ®Google Scholar
• Pascussi J-M, Drocourt L, Fabre J-M, et al. Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol [Internet]. 2000;58(2):361–372. Available from: http://www.molpharm.org
   PubMed Web of Science ®Google Scholar
• Pascussi J-M, Gerbal-Chaloin S, Fabre J-M, et al. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on Cytochrome P450 gene regulation. Mol Pharmacol [Internet]. 2000;58(6):1441–1450. Available from. doi: 10.1124/mol.58.6.1441
   PubMed Web of Science ®Google Scholar
• El-Sankary W, Plant NJ, Gibson GG, et al. Short communication regulation of the CYP3A4 gene by hydrocortisone and Xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000;28(5):493–496.
   PubMed Web of Science ®Google Scholar
• Ferguson SS, Chen Y, LeCluyse EL, et al. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4α. Mol Pharmacol. 2005;68(3):747–757. doi: 10.1124/mol.105.013169
   PubMed Web of Science ®Google Scholar
• Shi Z, Yang W, Goldstein JA, et al. Med25 is required for estrogen receptor alpha (ERα)-mediated regulation of human CYP2C9 expression. Biochem Pharmacol. 2014;90(4):425–431. doi: 10.1016/j.bcp.2014.06.016
   PubMed Web of Science ®Google Scholar
• Alshabi A, Shaik IH, Zhao Y, et al. A cocktail probe approach to evaluate the effect of hormones on the expression and activity of CYP enzymes in human hepatocytes with conditions simulating late stage of pregnancy. Eur J Clin Pharmacol. 2023;79(6):815–827. doi: 10.1007/s00228-023-03489-1
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Kakizaki S, Yoshinari K, et al. Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene [internet]. 2000. Available from: https://academic.oup.com/mend/article/14/11/1897/2751103
   Google Scholar
• Margaillan G, Rouleau M, Klein K, et al. Multiplexed targeted quantitative proteomics predicts hepatic glucuronidation potential. Drug Metab Dispos. 2015;43(9):1331–1335. doi: 10.1124/dmd.115.065391
   PubMed Web of Science ®Google Scholar
• Chen H, Yang K, Choi S, et al. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17β-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009;37(9):1841–1847. doi: 10.1124/dmd.109.026609
   PubMed Web of Science ®Google Scholar
• Awasthi R, An G, Donovan MD, et al. Relating observed psychoactive effects to the plasma concentrations of delta-9-tetrahydrocannabinol and its active metabolite: an effect-compartment modeling approach. J Pharm Sci. 2018;107(2):745–755. doi: 10.1016/j.xphs.2017.09.009
   PubMed Web of Science ®Google Scholar
• Singla S, Block R. Effect compartment model for the evaluation of tolerance to psychological highness following smoking marijuana. J Clin Pharmacol. 2022;62(12):1539–1547. doi: 10.1002/jcph.2109
   PubMed Web of Science ®Google Scholar
• Chiang CWN, Barnett G. Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin Pharmacol Ther. 1984;36(2):234–238. doi: 10.1038/clpt.1984.168
   PubMed Web of Science ®Google Scholar
• Gray TR, Lagasse LL, Smith LM, et al. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the infant development, environment and lifestyle (IDEAL) study. Ther Drug Monit [Internet]. 2009;31(6):769–775. doi: 10.1097/FTD.0b013e3181bb438e
   PubMed Web of Science ®Google Scholar
• Gray TR, Eiden RD, Leonard KE, et al. Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem. 2010;56(9):1442–1450. doi: 10.1373/clinchem.2010.147876
   PubMed Web of Science ®Google Scholar
• Bailey JR, Cunny HC, Paule MG, et al. Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol. 1987;90(2):315–321. doi: 10.1016/0041-008X(87)90338-3
   PubMed Web of Science ®Google Scholar
• Sheagren JN. Human placental transfer of cannabinoids. New English J Med. 1984;797:311.
   Google Scholar
• Kumar AR, Sheikh ED, Monson JW, et al. Understanding the mechanism and extent of transplacental transfer of (−)-∆ 9 -tetrahydrocannabinol (THC) in the perfused human placenta to predict in vivo fetal THC exposure. Clin Pharmacol Ther. 2023;114(2):446–458. doi: 10.1002/cpt.2964
   PubMed Web of Science ®Google Scholar